Shield Therapeutics plc

Shield Therapeutics plc

SHIEF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$44.13M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Shield Therapeutics plcShield Therapeutics plc-4.3-186%--1.5

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$44.13 Million
Enterprise Value$60.78 Million
Earnings per Share$-0.02
Beta1.72
Outstanding Shares1,068,588,418

Return

Return on Equity185.96%ROE
Return on Assets-59.01%
Return on Invested Capital-234.06%

Valuation & Multiples

P/E Ratio-4.31P/E Ratio
PEG5.54PEG
Price to Sales-Price to Sales
Price to Book Ratio-0.04Price to Book Ratio
Enterprise Value to Revenue0.6
Enterprise Value to EBIT-3.28
Enterprise Value to Net Income-2
Total Debt to Enterprise0.41
Debt to Equity-1.46Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
August 20, 2026
EPS
-$0.01
Reported
Revenue
$30.37 M
Est. $30.40 M

Next Earnings Call

Expected Date
April 29, 2027
EPS Estimate
-
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Shield Therapeutics plc

61 employees
CEO: Anders Lundstrom

Shield Therapeutics plc operates as a specialized pharmaceutical firm, dedicated to developing and bringing to market advanced clinical therapies that address significant unfulfilled medical requirements. Its flagship product, Accrufer/F...